The group reported a 7.9% increase in first-quarter revenue at constant exchange rates, driven by consumables. Profitability remains high and full-year guidance is maintained despite an uncertain environment.
Sartorius Stedim Biotech has posted improved quarterly results year-on-year. In the first quarter of 2026, revenue reached 762 million euros, up 7.9% at constant exchange rates compared to the previous year. This growth was primarily driven by recurring business in bioprocessing consumables. On a reported basis, including currency effects, growth stood at 2.3%. All regions contributed to this momentum, with activity rising by 9.1% in Europe, Middle East and Africa (EMEA), 5.6% in the Americas, and 9.4% in Asia-Pacific.
A stronger second half expected
Underlying EBITDA came in at 233 million euros, representing a margin of 30.7%. Net profit reached 88 million euros. "Despite an uncertain geopolitical and macroeconomic environment, we are maintaining a robust margin and confirming our 2026 targets," noted CEO René Faber, adding, "we continue to expect the second half of the year to outperform the first half in absolute terms."
The group is targeting annual revenue growth of between 6% and 10%, driven mainly by consumables, with an EBITDA margin exceeding 31%, supported by volume and scale effects. The current consensus forecast stands at a 31.4% margin for the year.
René Fáber is Chief Executive Officer & Director at Sartorius Stedim Biotech SA since 2023. Holds the position of Chairman at Sartorius Stédim FMT SAS. Serves as Vice Chairman at Sartorius Stedim Biotech (Beijing) Co., Ltd. Holds Director roles at Sartorius Stedim Japan KK, Sartorius Korea Biotech Co., Ltd., Sartorius Stedim (Shanghai) Trading Co., Ltd., Sartorius Albumedix Ltd., Sartorius Korea Operations LLC, and Sartorius Stedim BioOutsource Ltd. Member-Executive Board at Sartorius AG since 2002. Former Chairman-Supervisory Board at Sartorius Xell GmbH. Former Co-Managing Director & Member-Supervisory Board at Sartorius Stedim Biotech GmbH. Former Co-Managing Director at Sartorius Stedim North America Holding GmbH. Account Manager at Genentech, Inc. from 2016 to 2018. Vice President-Marketing & Product Management at Filtration Technology Corp. from 2014 to 2017. Education includes a doctorate from Technische Universität München and a graduate degree from Slovak University of Technology.
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically.
For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis.
With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key production sites are located in Germany, France and Puerto Rico.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
